報價延遲最少15分鐘:2025/09/04 01:39 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.33/-0.49
|
|
企業價值
240.08M
|
| 資產負債 |
|
每股賬面淨值
0.77
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/04 01:39 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases. |
